Literature DB >> 27009501

Different lasers in the treatment of benign prostatic hyperplasia: a network meta-analysis.

Xingming Zhang1, Pengfei Shen1, Qiying He1, Xiaoxue Yin2, Zhibin Chen1, Haojun Gui1, Kunpeng Shu1, Qidun Tang1, Yaojing Yang1, Xiuyi Pan2, Jia Wang1, Ni Chen2, Hao Zeng1.   

Abstract

All available surgical treatments for benign prostatic hyperplasia (BPH) have their individual advantages or disadvantages. However, the lack of head-to-head studies comparing different surgeries makes it unavailable to conduct direct analysis. To compare the efficacy and safety among different lasers and transurethral resection of prostate (TURP) for BPH, randomized controlled trials were searched in MEDLINE, EMBASE, Cochrane library, WHO International Clinical Trial Registration Platform, and Clinical Trial.gov by 2015.5; and the effectiveness-, perioperation- and complication-related outcomes were assessed by network meta-analysis. 36 studies involving 3831 patients were included. Holmium laser through resection and enucleation had the best efficacy in maximum flow rate. Thulium laser through vapo-resection was superior in improving international prostate symptom score and holmium laser through enucleation was the best for post-voiding residual volume improvement. Diode laser through vaporization was the rapidest in removing postoperative indwelling catheter, while TURP was the longest. TURP required the longest hospitalization and thulium laser through vapo-resection was relatively shorter. Holmium and thulium lasers seem to be relatively better in surgical efficacy and safety, so that these two lasers might be preferred in selection of optimal laser surgery. Actually, more large-scale and high quality head-to-head RCTs are suggested to validate the conclusions.

Entities:  

Mesh:

Year:  2016        PMID: 27009501      PMCID: PMC4806333          DOI: 10.1038/srep23503

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


Benign prostatic hyperplasia (BPH) is one of the most important causes of lower urinary tract symptoms (LUTS) in men, especially the elder men. Although BPH is not considered as a life-threatening disease, its impact on patients’ quality of life should not be underestimated1. Treatments for BPH include watchful waiting, drug therapy and surgery. Although a majority of patients with BPH could be treated with watchful waiting or drug therapies (alpha-blockers, 5-alpha-reductase inhibitors, anticholinergics, phytotherapeutics alone or combinations), there is still a certain number of patients finally required surgical intervention, such as transurethral resection of prostate (TURP) and surgeries lasers2. Even though TURP is still frequently used as traditional surgical therapy for BPH, in the past two decades, several novel lasers including holmium laser, thulium laser, KTP/Nd:YAG laser, Nd:YAG laser, diode laser and green light laser, have also shown excellent clinical effectiveness for BPH. All these available surgical treatments have their individual advantages or disadvantages. Abundant options faced by surgeons and patients result in the question that which treatment is relatively the best choice for BPH. However, because it is lack of head-to-head comparisons among different surgeries and the information about their comparative effectiveness is limited, direct statistical analysis is not available. Fortunately, a novel analysis method, network meta-analysis, might allow us to conduct a systematic review to compare the efficacy and safety among different surgical treatments for BPH.

Results

Study characteristics

1286 studies were identified through electronic searches and nine studies through additional searching. Thirty-six studies with 40 published articles (3831 participants) were finally included in our study3456789101112131415161718192021222324252627282930313233343536373839404142 (Fig. 1). The characteristics of the included studies were summarized in Table 1. Efficacy and safety of lasers were compared with TURP in 33 studies. Only three studies compared between different lasers (Fig. 2A).
Figure 1

Flow diagram of search in the scientific literature to identify randomized controlled trials.

Table 1

Characteristics of included studies.

StudiesInterventionsNBaseline characteristics
Age (years)Surgical techniques of LasersQ max (ml/s)IPSS scorePVR (ml)Prostate volume (cc)
Ahyai2007 + Kuntz 2004Holmium laser vs TURP20068.3 ± 91.8E5.4 ± 30.6NA226 ± 2423.551.7 ± 201.5
Al-Ansari 2010Green light vs TURP12066.7 ± 8.7V6.7 ± 2.127.6 ± 2.555.1 ± 23.161.1 ± 21.0
Anson 1995Nd:YAG vs TURP15168.1 ± 7.5V9.7 ± 3.8NA116.8 ± 104.276.2 ± 11.3*
Bachmann 2014Green light vs TURP26965.7 ± 6.7V9.7 ± 3.321.4 ± 6.1110.0 ± 96.247.4 ± 19.2
Bouchier-Hayes 2006Green light vs TURP7665.7 ± 43.1VNA38.7 ± 93.165.7 ± 43.1NA
Bouchier-Hayes 2010Green light vs TURP11965.7 ± 54.2V8.8 ± 2.825.3 ± 5.865.7 ± 54.28.8 ± 2.8
Capita´n 2011Green light vs TURP10068.7 ± 7.7V6.0 ± 3.623.6 ± 4.868.7 ± 7.76.0 ± 3.6
Carter 1999KTP/Nd:YAG vs TURP20467.4 ± 7.6V9.4 ± 3.0NA67.4 ± 7.69.4 ± 3.0
Cowles 1995Nd:YAG vs TURP11566.4 ± 7.3VNA19.8 ± 5.566.4 ± 7.3NA
Elshal 2015Green light vsHolmium laser10372.6 ± 9.1V + Evs E7.8 ± 2.322.7 ± 5.272.6 ± 9.17.8 ± 2.3
Eltabey 2010Holmium laser vs TURP8067.9 ± 8.6E8.3 ± 2.524.0 ± 4.567.9 ± 8.68.3 ± 2.5
Fraundorfer 2001Holmium laser vs TURP120NAR9.0 ± 3.1NANA9.0 ± 3.1
Gilling 1998Nd:YAGvs Holmium laser4466 ± 42.7R vs VNANA155.0 ± 158.545.5 ± 64.0
Gupta 2006Holmium laser vs TURP10066.5 ± 9.1E4.8 ± 4.223.9 ± 4.166.5 ± 9.14.8 ± 4.2
Horasanli 2007Green light vs TURP7668.8 ± 6.9V8.9 ± 5.419.5 ± 6.068.8 ± 6.98.9 ± 5.4
Keoghane 1996 + 2000Nd:YAG vs TURP8769.8#V11.6 ± 4.7NANA53.0 ± 25.1
Kursh 2003Diode laser vs TURP7268.5 ± 46.5VNANA68.5 ± 46.5NA
Liatsikos 2012Green light vs TURP6068.8 ± 7.9VNANA68.8 ± 7.9NA
Liedberg 2003Nd:YAG vs TURP31NAV8.0 ± 3.018.3 ± 8.0NA8.0 ± 3.0
Lukacs 2012Green light vs TURP13667.3 ± 7.7V7.8 ± 2.721.0 ± 2.467.3 ± 7.77.8 ± 2.7
Mohanty 2012Green light vs TURP11766.2 ± 8.8V7.1 ± 1.920.4 ± 3.666.2 ± 8.87.1 ± 1.9
Pereira-Correia 2012Green light vs TURP2065.3 ± 43.9V8.7 ± 13.422.8 ± 36.365.3 ± 43.98.7 ± 13.4
Razzaghi 2007Nd:YAG vs TURP8766.6 ± 8.2V6.1 ± 5.6NA165.0 ± 116.235.6 ± 8.2*
Razzaghi 2014Diode laser vs TURP11568.3 ± 8.3V6.5 ± 2.124.1 ± 6.859.4 ± 61.360.3 ± 15.1
Rigatti 2005Holmium laser vs TURP10064.8 ± 6.9E8.0 ± 3.421.7 ± 6.9NA58.3 ± 29.6
Shingleton 1999KTP/Nd:YAG vs TURP10067.8 ± 7.6V7.5 ± 3.7NANA30.9 ± 18.6
Sun 2014Holmium laser vs TURP16472.0 ± 7.5E5.5 ± 1.724.5 ± 3.8111.9 ± 109.1NA
Tan2003 + Wilson 2006  + Gilling 2012Holmium laser vs TURP6171.0 ± 5.8E8.4 ± 2.5NANA73.8 ± 29.3
Telli 2015Green light vs TURP10168.2 ± 60.2V11.8 ± 30.619.4 ± 37.463.1 ± 383.556.9 ± 60.4
Tuhkanen 1999-aNd:YAG vs TURP4567.0 ± 34.4V7.8 ± 15.4NA135.1 ± 491.455.0 ± 57.8
Tuhkanen 1999-bNd:YAG vs TURP5067.0 ± 25.9V8.6 ± 3.5NA116.5 ± 88.627 ± 31.6
Van Melick 2003Nd:YAG vs TURP9566.5 ± 8.5V11.5 ± 4.017.8 ± 6.4NA37.0 ± 11.0
Xia 2007Thulium laser vs TURP10069.7 ± 7.5V + R8.1 ± 2.921.4 ± 6.389.2 ± 34.4NA
Xue 2013Green light vs TURP20071.6 ± 11.0V8.1 ± 3.723.1 ± 5.0149.7 ± 103.166.6 ± 24.1
Yan 2013Thulium laser vs TURP8073.5 ± 7.3V + R7.7 ± 2.722.2 ± 4.974.4 ± 35.1NA
Zhang 2011Holmium laser vsThulium laser13374.2 ±  9.8E vs E7.0  ± 3.724.1 ± 3.064.6 ± 33.044.7 ± 23.6

Age, Q max, IPSS, PVR and Prostate volume-mean ± SD. *Prostate volume-gram; #data only reported mean, no SD or other kind of data; NA-data not available; E-Enucleation; V-Vaporization; R-Resection.

Figure 2

Network of treated comparisonsand risk of bias in included studies.

(A) TURP was the most common comparison, and direct comparisons among laser techniques were less. Numbers beside the lines were the amounts of studies among comparisons. Degree of thickness of line also indicated quantity of studies among comparisons. (B) Five items introduced by Cochrane Hanbook were considered. Blinding was canceled due to impractical implementation.

Among reported lasers, Nd:YAG was the earliest laser used in the treatment of BPH3. Almost all studies investigated laser as monotherapy compared with standard treatment (TURP), and only two studies applied combined strategy—KTP plus Nd:YAG. Green light laser technique was the most commonly used technology and was reported in 13 studies, and seven studies exactly recorded the wavelength (532 nm). Studies varied in ways of treatment, surgical techniques and publication years (from 1995 to 2015); however, the baseline characteristics of all patients were basically similar among interventions. The main surgical technique of lasers was vaporization; enucleation and resection were mainly conducted by Holmium laser. One study stopped early due to the need for prolonged catheterization and a high rate of urinary tract infection4. Risk of bias in included studies was summarized graphically in Fig.2B. One study had high risk of bias for sequence allocation and concealment, as it was reported as an open-label clinical trial5. Another trial was considered with high risk of other bias due to early discontinuation of study4. Since it was sometimes difficult to blind surgeons and patients, we did not include the blinding items of risk of bias in our analysis.

Effectiveness-related outcomes

Three effectiveness-related outcomes, including Q max, IPSS and PVR, were analyzed in the study. Based on node-split analyses, no significant inconsistencies were observed in effectiveness-related outcomes (p > 0.5). Q max was reported in 24 studies, involving seven interventions—green light, holmium laser, thulium laser, diode laser, Nd:YAG, KTP/Nd:YAG and TURP through different surgical techniques. Among them, holmium laser (resection and enucleation) was significantly superior to other lasers and TURP in improving Q max, and green light laser through vapo-enucleation was the worst one technique. The relative effect estimate of holmium laser (vaporization) versus green light laser (vapo-enucleation) was 16.69 (8.78, 25.00). Rank probability of Q-max (from best to worst) among lasers was holmium laser (resection)>holmium laser (enucleation)>thulium laser (vapo-resection)>Nd:YAG (vaporization)>TURP>green light (vaporization)>diode laser (vaporization)>green light (vapo-enucleation). (Fig. 3A)
Figure 3

Rank of probability for effective outcomes.

(A) rank probability of Q max; (B) rank probability of IPSS; (C) rank probability of PVR. All six kinds of lasers through different surgical techniques and TURP were availably compared in the network meta-analysis including Q max, IPSS and PVR. Q max-maximum flow rate. IPSS-International Prostate Symptom Score. PVR-Post-Void Residual.

In terms of IPSS score, thulium laser through vapo-resection showed significant superiority in improving IPSS over other interventions, rank probability (from best to worst): thulium laser (vapo-resection)>holmium laser (enucleation)>green light laser (vaporization)>TURP>green light laser (vapo-enucleation)>KTP/Nd:YAG (vaporization)>Nd:YAG (vaporization)>diode laser (vaporization) (Fig. 3B). For PVR, holmium laser through enucleation was the best technique and Nd:YAG (vaporization) was the worst one. The relative effect estimate was 40.36 (12.06, 71.23). Rank probability (from best to worst): holmium laser (enucleation)>thulium laser (vapo-resection)>KTP/Nd:YAG (vaporization)>diode laser (vaporization)>green light laser (vaporization)>TURP>green light laser (vapo-enucleation)>Nd:YAG (vaporization)(Fig. 3C).

Perioperation-related outcomes

Perioperation-related outcomes included operating time, duration of catheterization and stay of hospital. Consistency model was used for all perioperation-related outcomes. Twenty-five studies investigated operating time of lasers and TURP in the treatment of BPH. For operating time, seven interventions through different surgical techniques were availably compared—holmium laser, thulium laser, green light laser, Nd:YAG, diode laser and TURP. Nd:YAG laser through vaporization and TURP had much fewer operating time than others, while holmium laser (resection) took the longest time; the relative effect estimates of Nd:YAG laser (vaporization) and TURP versus holmium laser (resection) were −22.3 (−48.87, 4.37) and −11.45 (−21.04, −2.04), respectively. Rank probability: (from shortest to longest) Nd:YAG (vaporization)>TURP>diode laser (vaporization)>green light laser (vaporization)>thulium laser (vaporesection)>green light laser (vaporization)>holmium laser (enucleation)>holmium laser (resection) (Fig. 4A).
Figure 4

Rank of probability for perioperation-related outcomes.

(A) rank probability of operating time; (B) rank probability of catheterization; (C) rank probability of hospitalization. Five kinds of lasers through different surgical techniquesand TURP were included for network meta-analysis about perioperation-related outcomes. Nd:YAG/KTP laser was not available.

For catheterization, patients underwent diode laser (vaporization) were the rapidest technique in removing catheter after surgery, and TURP was the longest one; the relative effect estimate of TURP vs diode laser was 68.90 (47.35, 90.84). Rank probability from short to long: diode laser(vaporization)>green light laser(vaporization)>thulium laser(vaporesection)>holmium laser(enucleation)>holmium laser(resection)>TURP>Nd:YAG(vaporization)>green light laser(vapo-enucleation) (Fig. 4B). In terms of hospitalization, TURP required the longest time of stay in hospital, while thulium laser was relatively shortest, relative effect estimate was 46.56 (7.18, 86.27). Rank probability(from shortest to longest),: thulium laser (vapo-resection)>green light laser (vaporization)>diode laser (vaporization)>holmium laser (enucleation)>holmium laser (resection)>green light laser (vapo-enucleation)>Nd:YAG (vaporization)>TURP (Fig. 4C).

Short-term complications-related outcomes

Short-term complications-related outcomes, including dysuria, urinary retention, re-catheterization, clot retention, transfusion, incontinence, TURS, and UTI were analyzed. Total of nine studies reported dysuria, which was availably compared in five interventions through different techniques (holmium laser, green light laser, KTP/Nd:YAG, Nd:YAG laser and TURP).The network analysis showed that dysuria was the most common short-term complication in patients who underwent green light laser(vapo-enucleation) and holmium laser(enucleation), and the least common in Nd:YAG laser with vaporization. The relative effect estimates of Nd:YAG(vaporization) versus green light laser (vapo-enucleation) and holmium (enucleation) were 0.00 (0.00, 0.20) and 0.06 (0.00, 16.93), respectively. The Nd:YAG laser through vaporization technique was the most common technique inducing urinary retention. Besides, re-catheterization was always seen in patients underwent green light laser (vaporization) and diode laser (vaporization); and it was barely occurred in Nd:YAG laser (vaporization), basically corresponding with the outcome of dysuria but not urinary retention (Fig. 5A–C). KTP/Nd:YAG (vaporization) and green light (vaporization) were mostly related with post-operation incontinence(Fig. 5D).
Figure 5

Rank of probability for short-term complicationsrelated tovoiding symptoms.

(A) rank probability of dysuria; (B) rank probability of urinary retention; (C) rank probability of re-catheterization; (D) rank probability of incontinence.Thulium laser was absentfor dysuria and urinary retension. Nd:YAG/KTP was not available for re-catheterization.

Transfusion was mostly seen in TURP but rarely in diode laser(vaporization) and thulium laser (vapo–resection); Nd:YAG laser (vaporization) and TURP had much higher rates of occurrence of clot retention, while holmium laser (enucleation) had the least rate(Fig. 6A,B). In addition, TURS was most seen in patients treated with TURP (Fig. 6C). While considering UTI, the most related technique was Nd:YAG laser through vaporization (Fig. 6D).
Figure 6

Rank of probability for other short-term complications-related outcomes.

(A) rank probability of transfusion; (B) rank probability of clot retention; (C) rank probability of TURS; (D) rank probability of UTI. Thulium laser was absent for clot retension andNd:YAG/KTP was not available for clot retention, transfusion and TURS. Holmium laser was not included in TURS outcome.

Long-term and other complications-related outcomes

Long-term complications-related outcomes, including bladder neck contracture or stenosis and urethral stricture or meatal stenosis, were analyzed in our network meta-analysis. Bladder neck contracture or stenosis was frequently occurred in KTP/Nd:YAG (vaporization) and holmium laser (enucleation); while green light (vaporization) and diode laser (vaporization)were on the contrary (Fig. 7A). The relative effect estimate of green light (vaporization) versus KTP/Nd:YAG (vaporization) was 0.47 (0.02, 5.05). Intriguingly, green light through vaporization plus enucleation had fewer bladder neck contracture or stenosis than vaporization alone. TURP was mostly associated with urethral stricture or meatal stenosis, and diode laser (vaporization) had the least incidence (Fig. 7B). Analysis of green light through different techniques showed that combination of vaporization and enucleation had less urethral stricture or meatal stenosis, compared to vaporization alone.
Figure 7

Rank of probability for long-term and other complications-related outcomes.

(A) rank probability of bladder neck contracture or meatal stenosis; (B) rank probability of urethral stricture or meatal stenosis; (C) rank probability of re-operation. Thulium laser was not availably compared for outcome bladder neck contracture or meatal stenosis. All six kinds of lasers through different surgical techniquesand TURP were availably compared in the network meta-analysis of outcomes urethral stricture or meatal stenosis and re-operation.

Re-operation was analyzed as other complications-related outcomes and was reported in 13 studies5911161821222832333435363841. However, the reasons for re-operation were not adequately interpreted in all included studies. Therefore, it was difficult to split it into subgroup analysis, and network meta-analysis was conducted for the overall re-operation rate, which was mostly seen in diode laser (vaporization) and thulium laser (vapo-resection) (Fig. 7C).

Discussion

TURP is always considered as the gold standard surgical treatment for patients with BPH; however, it is still associated with significant morbidity and mortality, such as TURS and transfusion. In the past two decades, both researchers and surgeons devoted to developing novel surgical treatments for pursuing a much better efficacy, as well as much more improvement of safety. Since Nd:YAG laser was firstly reported being used in the treatment of BPH by Costello and colleagues in 199243, more lasers were introduced to treat BPH with improved surgical safety and efficacy. Afterwards, the improvement of technology led the appearance of innovative lasers applying in surgical practice of BPH. At present, the most often used lasers are holmium laser, green light laser and thulium laser with different surgical techniques, both in clinical practice and academic research44. However, among diverse kinds of laser techniques, there is no completely or absolutely perfect intervention. Each laser has its advantages or disadvantages with different clinical outcomes. How to select the best surgical treatment for BPH is difficult but be of importance. Thus, it is worthy of comparing different surgical techniques, no matter direct or indirect studies. And to our knowledge, this is the first study, applying Bayesian analytical method of network meta-analysis, to indirectly compare the efficacy and safety of different lasers with TURP in the treatment of BPH. Based on our network meta-analysis, holmium laser achieved a better Q max and less PVR, and thulium laser achieved a lower IPSS than other lasers with different techniques and TURP. In the aspect of peri-operation-related outcomes, holmium laser through resection technique took the longest operating time and thulium laser (vapo-resection) ranked in the middle. It was also proven by a direct analysis that thulium laser required a longer operating time than holmium laser (72.4 vs 61.5 minutes, p = 0.034)42. However, both the two techniques had shorter time of indwelling catheter and time of stay in hospital resulting in a reduced incidence of complications. So, holmium laser and thulium laser showed a better surgical efficacy and had a higher safety with the least incidence of complications. The resection and enucleation techniques of thulium and holmium lasers were seen as similar as open prostatectomy in the complete removal of the prostatic lobes313942. The thulium laser could perform a smooth incision or vaporization by continuous mode42. This might decrease the occurrence of LUTS and improve IPSS after operation. The holmium laser always was characterized as scar-free disruption and its incision could reach the surgical capsule of prostate3139. And this might increase the outflow of bladder and reduce the PVR. But all these advantages were still not enough to explain the better effectiveness of holmium laser and thulium laser techniques in improving patients’ obstructive symptoms. For peri-operation-related outcomes and the incidences of complications, green light laser through vapo-enucleation was more frequent associated with dysuria. Urinary retention was frequently seen in Nd:YAG laser alone or combined with KTP technique. Also, re-placement of catheter was mainly associated with green light laser and diode laser techniques. It was very likely that these two techniques could easily induce tissue edema and cause deficient effect when resecting the apex of prostate. Nd:YAG/KTP, diode laser, green light laser and TURP were observed with more complications (particularly green light laser) only with medium efficacies. As shown in the analysis, we compared six kinds of laser techniques and TURP. Nowadays, since the numerous postoperative complications of the initial laser procedures and the improvement of new equipment, some lasers had to be eliminated. Nd:YAG laser technique was firstly applied in the surgical treatment of BPH and is now abandoned in clinical practice, for its incapability in ablating prostate tissue immediately, postoperative frequency and urgency led by deep tissue necrosis and high rate of re-operation45. As show in the study, Nd:YAG technique achieved the worst surgical effect. In contrast to obsolete laser procedures, the current higher powered lasers—holmium laser, thulium laser, green light laser and diode laser—are able to ablate prostatic tissue rapidly. Holmium laser is optimized for incision, and green light laser is optimized for vaporization. Previously researches showed that these two techniques had the superiorities over other lasers in the respect of functional outcomes, which were inconsistent with the results of our analysis44. According to the results of our network meta-analysis, it seemed that the choice of laser techniques for BPH should be depended on what kinds of aims the patient wanted to get benefit, such as TURP may not be the best choice for patients with previous documented or suspected urethral stricture or meatal stenosis, as its incidence of postoperative urethral stricture or meatal stenosis was the highest. There were some limitations in this network meta-analysis, such as included RCTs studied from 1995 to 2015, evident differences in sample sizes and significant transformation in techniques of the same lasers (green light laser improved form initial 80-W to 120-W, and subsequently to the current laser at 180-W)5789101318222425263540. Although all authors were contacted to provide un-reported data for the integrity of analysis, the results of this study were restricted by incomplete data reported by included studies. Also, time-points of analyzed outcome measures were restrained to 12 months, for the limited data reported. But this review still enjoyed several advantages—rigidly analytical process by pre-published protocol, analyses of both lasers and TURP, and indirect comparisons in predicting efficacies of one technique to another due to the absence of head-to-head RCTs. Furthermore, it might be encouraged for us to offer referable ideas for future researches and valuable advice for clinical surgeons by using this first comprehensive systematic review and network meta-analysis to assess the efficacy and safety of different laser techniques and TURP for BPH. In conclusion, this is the first time to indirectly compare the efficacy and safety of different lasers with TURP for BPH by applying network meta-analysis. To date, no completely or absolutely perfect laser technique could be found to take the place of TURP in the surgical treatment of BPH. Holmium laser and thulium laser may seem to be relatively better in terms of surgical efficacy and safety, so that these two lasers might be preferred in the selection of optimal laser surgery. Actually, much longer-term, larger-scale and higher quality head-to-head RCTs are needed to validate the conclusions.

Methods

Protocol and registration

We developed a protocol defining the search strategy and a systematic review was performed to identify those randomized controlled trials (RCTs) investigating the efficacy and safety of different lasers or TURP for BPH. The review was registered on PROSPERO of the Centre for Reviews and Dissemination (CRD) (CRD42015024227). The data searching, study selection, quality assessment of included studies and data extraction were performed independently by two researchers (Z.X.M. and S.P.F.). Disagreements were resolved by discussing or with the help of a third investigator to reach the final consensus.

Eligibility and exclusion criteria

The eligibility criteria included: 1) Patients with BPH needed surgery intervention; 2) RCTs comparing different lasers and TURP (comparing different laser with one another), either laser alone or in combination with others, for the treatment of BPH; 3) Each laser may be through different surgical techniques:vaporization, resection of tissue pieces, enucleation, or combinations; 4) Published in English, German, French, Italian, Russian, Dutch, and Japanese. Exclusion criteria: 1) Patients with neurogenic bladder disorder, urethral strictures, history of prostate adenocarcinoma or any previous prostatic, and bladder neck or urethral surgery. 2) Non-RCTs, reviews, reports only focusing on laboratory findings, trials published only as abstracts. 3) Not published in English, German, French, Italian, Russian, Dutch, and Japanese. Outcome measures included: 1) Effectiveness-related outcomes: maximum flow rate (Q max), International Prostate Symptom Score (IPSS), post-void residual volume (PVR); 2) Perioperation-related outcomes: operating time, hospitalization and catheterization; 3) Complications-related outcomes: ① short-term complications-related outcomes (always occurred within one month after operation): dysuria, re-catherization, urine retention, clot retention, transfusion, transurethral resection syndrome (TURS), urine incontinence, and urinary tract infection (UTI); ② long-term complications-related outcomes (always occurred after one month of operation): bladder neck contracture or stenosis, urethral stricture or meatal stenosis; ③ other complication-related outcome: re-operation because of any other complications.

Data resources and searches

MEDLINE (1966–2015.5) and EMBASE (1947–2015.5) were searched. Further searches were undertaken in the Cochrane Central Register of Controlled Trials (CENTRAL) (1948–2015.5), WHO International Clinical Trial Registration Platform (ICTRP) (2004–2015.5), and Clinical Trial.gov (1999–2015.5). The following terms and keywords were used: laser, transurethral resection of prostate, TURP, benign prostatic hyperplasia, and BPH. Included trials’ references were searched for more studies and experts in the field were consulted.

Study selection and data extraction

Two investigators independently assessed the titles and abstracts of the searched results. The full text versions of those studies, which were potentially eligible, were then assessed. For the study design, selection criteria, participant’s characteristics, interventions, outcome measures, study duration, results and other data of each included study were extracted. Extracted contents were recorded on data extraction forms, which were designed according to the advice given in the Cochrane Handbook46. We contacted authors to seek additional information where data were not reported or not clear.

Assessment of risk

Two independent reviewers (Z.X.M. and S.P.F.) used RevMan 5 software to assess the risk of bias of all included studies according to the Cochrane Handbook47, as follows: 1). adequate sequence generation; 2). allocation concealment; 3). incomplete outcome data; 4). free of selective reporting; 5). free of other bias. The judgments were categorized as ‘yes’ (low risk’ of bias), ‘no’ (high risk of bias) or ‘unclear’ (unclear risk of bias).

Data synthesis

ADDIS software (version 1.16.6) was applied to conduct indirect comparison analysis (network meta-analysis to compare different interventions not directly matched). Network meta-analysis led us to predict the likely comparable estimates between indirect comparisons based on two or more studies with one common intervention. Using Bayesian approach, the relative effect estimates were calculated and could be used to estimate the probability that which one was the best. Node-split analysis was utilized to check inconsistency among comparisons, and p < 0.05 was set as significant inconsistency.

Additional Information

How to cite this article: Zhang, X. et al. Different lasers in the treatment of benign prostatic hyperplasia: a network meta-analysis. Sci. Rep. 6, 23503; doi: 10.1038/srep23503 (2016).
  44 in total

1.  Long-term results of a randomized trial comparing holmium laser enucleation of the prostate and transurethral resection of the prostate: results at 7 years.

Authors:  Peter J Gilling; Liam C Wilson; Colleen J King; Andre M Westenberg; Christopher M Frampton; Mark R Fraundorfer
Journal:  BJU Int       Date:  2011-08-23       Impact factor: 5.588

2.  180-W XPS GreenLight laser vaporisation versus transurethral resection of the prostate for the treatment of benign prostatic obstruction: 6-month safety and efficacy results of a European Multicentre Randomised Trial--the GOLIATH study.

Authors:  Alexander Bachmann; Andrea Tubaro; Neil Barber; Frank d'Ancona; Gordon Muir; Ulrich Witzsch; Marc-Oliver Grimm; Joan Benejam; Jens-Uwe Stolzenburg; Antony Riddick; Sascha Pahernik; Herman Roelink; Filip Ameye; Christian Saussine; Franck Bruyère; Wolfgang Loidl; Tim Larner; Nirjan-Kumar Gogoi; Richard Hindley; Rolf Muschter; Andrew Thorpe; Nitin Shrotri; Stuart Graham; Moritz Hamann; Kurt Miller; Martin Schostak; Carlos Capitán; Helmut Knispel; J Andrew Thomas
Journal:  Eur Urol       Date:  2013-11-11       Impact factor: 20.096

3.  Hybrid laser treatment compared with transurethral resection of the prostate for symptomatic bladder outlet obstruction caused by a large benign prostate: a prospective, randomized trial with a 6-month follow-up.

Authors:  K Tuhkanen; A Heino; M Alaopas
Journal:  BJU Int       Date:  1999-11       Impact factor: 5.588

4.  GreenLight HPS 120-W laser vaporization versus transurethral resection of the prostate for the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia: a randomized clinical trial with 2-year follow-up.

Authors:  Carlos Capitán; Cristina Blázquez; M Dolores Martin; Virginia Hernández; Enrique de la Peña; Carlos Llorente
Journal:  Eur Urol       Date:  2011-06-01       Impact factor: 20.096

5.  A prospective randomized controlled trial of hybrid laser treatment or transurethral resection of the prostate, with a 1-year follow-up.

Authors:  A Carter; H Sells; M Speakman; P Ewings; R MacDonagh; P O'Boyle
Journal:  BJU Int       Date:  1999-02       Impact factor: 5.588

6.  KTP laser versus transurethral resection: early results of a randomized trial.

Authors:  David M Bouchier-Hayes; Paul Anderson; Scott Van Appledorn; Pat Bugeja; Anthony J Costello
Journal:  J Endourol       Date:  2006-08       Impact factor: 2.942

7.  A randomised trial comparing holmium laser enucleation versus transurethral resection in the treatment of prostates larger than 40 grams: results at 2 years.

Authors:  Liam C Wilson; Peter J Gilling; Andrew Williams; Katie M Kennett; Chris M Frampton; Andre M Westenberg; Mark R Fraundorfer
Journal:  Eur Urol       Date:  2006-05-02       Impact factor: 20.096

8.  Urologic diseases in America project: benign prostatic hyperplasia.

Authors:  John T Wei; Elizabeth Calhoun; Steven J Jacobsen
Journal:  J Urol       Date:  2005-04       Impact factor: 7.450

9.  A randomized trial comparing holmium laser enucleation of the prostate with transurethral resection of the prostate for the treatment of bladder outlet obstruction secondary to benign prostatic hyperplasia in large glands (40 to 200 grams).

Authors:  A H H Tan; P J Gilling; K M Kennett; C Frampton; A M Westenberg; M R Fraundorfer
Journal:  J Urol       Date:  2003-10       Impact factor: 7.450

Review 10.  Laser treatment of benign prostate enlargement--which laser for which prostate?

Authors:  Malte Rieken; Alexander Bachmann
Journal:  Nat Rev Urol       Date:  2014-03-04       Impact factor: 14.432

View more
  19 in total

1.  Benign prostatic hyperplasia surgical scoring (BPHSS): an novel scoring system for the perioperative outcomes of holmium laser enucleation of the prostate.

Authors:  Huan Xu; Zhikang Cai; Yanbo Chen; Meng Gu; Qi Chen; Zhong Wang
Journal:  Lasers Med Sci       Date:  2018-01-08       Impact factor: 3.161

Review 2.  Thulium (Tm:YAG) laser vaporesection of prostate and bipolar transurethral resection of prostate in patients with benign prostate hyperplasia: a systematic review and meta-analysis.

Authors:  Yu Lan; Wenqi Wu; Luhao Liu; Shiyu Zhou; Chuangxin Lan; Irene Raphael Ketegwe; Guohua Zeng
Journal:  Lasers Med Sci       Date:  2018-06-27       Impact factor: 3.161

3.  Detection of blackbody radiation during fiber guided laser-tissue vaporization.

Authors:  Paris Franz; Xiaomei Wang; Hui Zhu; Ray Chia; Tom Hasenberg; Hui Wang
Journal:  Biomed Opt Express       Date:  2020-01-14       Impact factor: 3.732

4.  A novel vaporization-enucleation technique for benign prostate hyperplasia using 120-W HPS GreenLight™ laser: Seoul technique II in comparison with vaporization and previously reported modified vaporization-resection technique.

Authors:  Sangjun Yoo; Juhyun Park; Sung Yong Cho; Min Chul Cho; Hyeon Jeong; Hwancheol Son
Journal:  World J Urol       Date:  2017-09-23       Impact factor: 4.226

5.  Transurethral vaporesection of prostate: diode laser or thulium laser?

Authors:  Xinji Tan; Xiaobo Zhang; Dongjie Li; Xiong Chen; Yuanqing Dai; Jie Gu; Mingquan Chen; Sheng Hu; Yao Bai; Yu Ning
Journal:  Lasers Med Sci       Date:  2018-04-10       Impact factor: 3.161

Review 6.  Epidemiology and treatment modalities for the management of benign prostatic hyperplasia.

Authors:  Soum D Lokeshwar; Benjamin T Harper; Eric Webb; Andre Jordan; Thomas A Dykes; Durwood E Neal; Martha K Terris; Zachary Klaassen
Journal:  Transl Androl Urol       Date:  2019-10

7.  The effectiveness and safety of three surgical procedures for the treatment for benign prostatic hyperplasia: A network meta-analysis.

Authors:  Jiusong Yan; Liang Gao; Guangyong Xu; Junyong Zhang
Journal:  Heliyon       Date:  2022-10-04

8.  BPH treatment: laser for everyone | Opinion: YES.

Authors:  Carlos A R Sacomani; Ricardo Vita Nunes
Journal:  Int Braz J Urol       Date:  2018 Mar-Apr       Impact factor: 1.541

9.  Thulium laser transurethral vaporesection versus transurethral resection of the prostate for benign prostatic obstruction: the UNBLOCS RCT.

Authors:  Jo Worthington; J Athene Lane; Hilary Taylor; Grace Young; Sian M Noble; Paul Abrams; Aideen Ahern; Sara T Brookes; Nikki Cotterill; Lyndsey Johnson; Rafiyah Khan; Aida Moure Fernandez; Tobias Page; Satchi Swami; Hashim Hashim
Journal:  Health Technol Assess       Date:  2020-09       Impact factor: 4.014

10.  Comparison of the efficacy and safety of transurethral laser versus open prostatectomy for patients with large-sized benign prostatic hyperplasia: A meta-analysis of comparative trials.

Authors:  Hai-Bin Wei; Bing-Yi Guo; Yao-Fen Tu; Xuan-Han Hu; Wei Zheng; Da-Hong Zhang; Jian Zhuo
Journal:  Investig Clin Urol       Date:  2022-04-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.